| Followers | 35 |
| Posts | 2237 |
| Boards Moderated | 0 |
| Alias Born | 10/18/2019 |
Friday, July 04, 2025 3:46:56 PM
Again ATL you are not correct.
As the fdatold the cei of mimivax they had to have patient level data for comparison. Liau in one of her talks spoke of controlled studies and how they should (but do not) share the patient level data she said nothing of rwd data only that from controlled studies. Liau also spoke of the eu and UK may be more open to the use of grouped data from other trials. You keep believing as you do even though incorrect
Just like the talks from Dr Liau where she says immunotherapy in gym sees perhaps 20 to 30% response rate and you said all respond. If so why in the 3 ucla spoke grant trials only 1 uses the vaccine
And yes nearly all here know the eca for the nwbo trial was from other controlled trials now rwd
As the fdatold the cei of mimivax they had to have patient level data for comparison. Liau in one of her talks spoke of controlled studies and how they should (but do not) share the patient level data she said nothing of rwd data only that from controlled studies. Liau also spoke of the eu and UK may be more open to the use of grouped data from other trials. You keep believing as you do even though incorrect
Just like the talks from Dr Liau where she says immunotherapy in gym sees perhaps 20 to 30% response rate and you said all respond. If so why in the 3 ucla spoke grant trials only 1 uses the vaccine
And yes nearly all here know the eca for the nwbo trial was from other controlled trials now rwd
Recent NWBO News
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
